Euclid Orthokeratology (oprifocon A) Contact Lenses for Overnight Wear and Euclid Orthokeratology (tisilfocon A) Contact
Euclid Vision Corporation · Decision date Mar 12, 2026
What did the FDA approve?
FDA records P040029/S025 as a supplement to PMA P040029, with the supplement type “Normal 180 Day Track”. The recorded decision is approval, dated Mar 12, 2026.
FDA approval order statement
updated branding, instructions for use, and alternate product labels for the Euclid Orthokeratology (oprifocon A) Contact Lenses for Overnight Wear and Euclid Orthokeratology (tisilfocon A) Contact Lenses for Overnight Wear
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track
- Clinical specialty
- Ophthalmic
- Decision date
- Mar 12, 2026
- FDA change category
- Labeling Change - Indications/instructions/shelf life/tradename
Regulatory record facts
- Identifier
- P040029/S025
- Regulatory pathway
- PMA supplement
- Applicant
- Euclid Vision Corporation
- Product code
- NUU
- Decision code
- APPR
- Decision date
- Mar 12, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Lens, contact, orthokeratology, overnight.
- Applicant
- Euclid Vision Corporation
- Product code
- NUU
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P040029/S025 received
Application receipt date recorded by FDA.
P040029/S021 · Related supplement
Euclid Orthokeratology (oprifocon A) Contact Lenses for Overnight Wear, Euclid Orthokeratology (tisilfocon A) Contact Le
P040029/S025 · FDA decision
Normal 180 Day Track
P040029/S026 · Related supplement
Euclid Orthokeratology (oprifocon A) Contact Lenses for Overnight Wear and Euclid Orthokeratology (tisilfocon A) Contact
Timeline entries are records held by MedtechLedger for P040029. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P040029
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Euclid Vision Corporation | PMA supplement | Mar 6, 2026 | FDA | |
| Euclid Vision Corporation | PMA supplement | Apr 2, 2026 | FDA |
Explore the linked device profile
Other records with product code NUU
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Tianjin MasterVision Technology Co., Ltd. | PMA approval | Aug 5, 2026 | FDA | |
| Contamac, Ltd. | PMA approval | Feb 10, 2026 | FDA | |
Boston Orthokeratology (oprifocon A)P010062/S015 | Bausch & Lomb | PMA supplement | Dec 16, 2025 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Euclid Vision Corporation
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 45472 Holiday Dr., Suite 7, Sterling, VA, 20166
Sources and methodology
- Original FDA record: P040029/S025
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


